Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Appili Therapeutics Inc. (APLI.TO)
Halifax, NS, CA
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -40.00% | -40.00% | +0.00% | -62.50% | -98.26% | -98.13% | -98.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+143.1% ★ Q1'26: +433.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-58.8% Q1'26: -515.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,268.5% Q1'26: -630.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2,675.6% Q1'26: -5,845.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +221.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.0% ★ Q1'26: +9.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.98× Q1'26: -1.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
199.1K
est: 200.0K (-0.4%)
|
1.39M
est: 828.0K (+68.0%)
|
334.2K
est: 334.2K (+0.0%)
|
100.4K
est: 100.4K (+0.0%)
|
244.2K
244.2K – 244.2K
+143.1% YoY
|
| EBITDA |
-5.63M
est: -40.0K (-13,975.5%)
|
-23.51M
est: -165.6K (-14,098.3%)
|
-8.10M
est: -66.8K (-12,025.8%)
|
360.6K
est: -20.1K (+1,894.9%)
|
-146.5K
-146.5K – -146.5K
-629.3% YoY
|
| EBIT |
-5.40M
est: -40.0K (-13,411.3%)
|
-23.52M
est: -165.6K (-14,105.9%)
|
-8.11M
est: -66.8K (-12,035.2%)
|
347.1K
est: -20.1K (+1,827.9%)
|
-146.5K
-146.5K – -146.5K
-629.3% YoY
|
| Net Income |
-5.42M
est: -16.98M (+68.1%)
|
-25.12M
est: -32.74M (+23.3%)
|
-9.24M
est: -9.70M (+4.7%)
|
-2.62M
est: -6.06M (+56.7%)
|
-6.19M
-6.19M – -6.19M
-2.0% YoY
|
| SGA |
4.25M
est: 2.03M (+109.5%)
|
5.32M
est: 8.41M (-36.6%)
|
4.62M
est: 3.39M (+36.3%)
|
2.85M
est: 1.02M (+179.8%)
|
2.93M
2.93M – 2.93M
+186.9% YoY
|
| EPS |
-0.16
est: -0.14 (-14.3%)
|
-0.38
est: -0.27 (-40.7%)
|
-0.08
est: -0.08 (-1.6%)
|
-0.02
est: -0.05 (+56.8%)
|
-0.05
-0.05 – -0.05
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donald D. Cilla Jr. Pharmd | Chief Executive Officer, President & Director | 714.9K | — |
| Gary S. Nabors | Chief Development Officer | 604.9K | — |
| Kenneth G. Howling | Acting Chief Financial Officer | 550.8K | male |
| Carl Gelhaus | Director of Non-Clinical Research | 351.5K | — |
| Arthur Baran | Director of New Product Development | 336.6K | male |
| Jenna McNeil | Corporate Affairs & Communications Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APLI.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
